<code id='F11059F529'></code><style id='F11059F529'></style>
    • <acronym id='F11059F529'></acronym>
      <center id='F11059F529'><center id='F11059F529'><tfoot id='F11059F529'></tfoot></center><abbr id='F11059F529'><dir id='F11059F529'><tfoot id='F11059F529'></tfoot><noframes id='F11059F529'>

    • <optgroup id='F11059F529'><strike id='F11059F529'><sup id='F11059F529'></sup></strike><code id='F11059F529'></code></optgroup>
        1. <b id='F11059F529'><label id='F11059F529'><select id='F11059F529'><dt id='F11059F529'><span id='F11059F529'></span></dt></select></label></b><u id='F11059F529'></u>
          <i id='F11059F529'><strike id='F11059F529'><tt id='F11059F529'><pre id='F11059F529'></pre></tt></strike></i>

          leisure time

          leisure time

          author:leisure time    Page View:212
          Three people in different suits, two standing up and the middle one sitting on a bench, looks to the camera — biotech coverage from STAT
          The founders of Syntis Bio, from left to right: Giovanni Traverso, Rahul Dhanda, and Bob Langer. Courtesy Douglas Levy

          A new company founded by a group of biotech veterans, including Bob Langer, came out of stealth mode Tuesday with plans to create pills for everything from obesity to rare diseases.

          The company, Syntis Bio, is based on a technology developed by Langer and MIT professor Giovanni Traverso that can coat the stomach and potentially other organ surfaces, changing the way that drugs are absorbed or, in the case of obesity, which hormones are triggered. The pair co-founded Syntis in 2022 with Rahul Dhanda, who is also the startup’s CEO.

          advertisement

          Syntis’ core approach is an oral polymer chemistry the team calls SYNT, which creates a coating over receptors in places like the stomach. It’s much like the mucosal adhesive that the crustaceans mussels use to stick onto rocks, Traverso said.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          GSK’s asthma push continues as drug succeeds in Phase 3 trials
          GSK’s asthma push continues as drug succeeds in Phase 3 trials

          AkiraSuemori/APAnewasthmatreatmentthatcouldbeadministeredjustonceeverysixmonthshassucceededintwoPhas

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          Most antidepressants don't work on kids, teens, study finds

          MattDtrich/TheIndianapolisStar/APThevastmajorityofantidepressantsgiventokidsandteensareineffectivean